Furthermore, the addition of CD43 (homogeneously expressed on CLL cells) [80] to CD19/CD5/CD20 has allowed to reach a 100% specificity in detecting residual CLL cells, when compared to molecular assays, with a maximum sensitivity of 2.2 × 10−4 [81]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.